­
­
­
­

Inventi Impact: Clinical Research

Articles

  • Inventi:pcr/33485/20
    Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study
    Research 2021 : January - March
    Ulrich-Frank Pape, Stefan Kasper, Johannes Meiler, Marianne Sinn, Arndt Vogel, Lothar Müller, Oswald Burkhard, Karel Caca, Steffen Heeg, Petra Büchner-Steudel, Victor Rodriguez-Laval, Anja A Kühl, Ruza Arsenic, Holger Jansen, Peter Treasure, Nalân Utku

    CAP7.1 is a novel topoisomerase II inhibitor, converted to active etoposide via\ncarboxylesterase 2 (CES2), with signals of efficacy in treatment-refractory solid tumours. In a Phase II\ntrial, 27 patients with advanced biliary tract cancers (BTC) were randomised 1:1 to CAP7.1 plus best\nsupportive care (BSC), or BSC alone, with crossover to CAP7.1 upon disease progression..........................

    How to Cite this Article
    Attribution/ CC Compliant Citation: Pape, Ulrich-Frank, et al. \"Efficacy and Safety of CAP7. 1 as Second-Line Treatment for\nAdvanced Biliary Tract Cancers: Data from a Randomised Phase II Study.\" Cancers 12.11 (2020): 3149.\nhttps://doi:10.3390/cancers12113149\nhttp://creativecommons.org/licenses/by/4.0/\nSome formatting elements, header, footer, logos, dates and pagination were modified while adapting this article.
    Download Full Text